Novel drug combination addresses gap in enterovirus treatment

A novel triple drug combination could be effective at halting enterovirus replication in human cell and organoid cultures.

In a study published in Cellular and Molecular Life Sciences, researchers examined the safety and efficacy of an orally bioavailable novel triple drug combination — which included pleconaril, AG7404 and mindeudesivir — against several enteroviruses in lung, eye, cervical, skeletal and pancreatic cells.

The researchers found that the drug combination worked synergistically to target the viruses without causing cytotoxicity. Further, the treatment delayed antiviral drug resistance and protected human organoids.

The findings suggested that the novel triple drug combination could be used as a broad-spectrum antiviral cocktail. Nonetheless, clinical trials in humans are needed to validate the results of the study.

Read more: Cellular and Molecular Life Sciences

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.